摘要
支气管哮喘是严重危害我国儿童健康的疾病。全文就目前国内外儿童支气管哮喘治疗药物进行综述,分析一线治疗药物的优势和不足,同时介绍国内外新型药物治疗方法,特别是新型生物制剂单克隆抗体的应用。为儿童支气管哮喘的临床治疗提供依据。
Bronchial asthma is a disease that seriously harms the health of children in China.The full text summarizes the current treatment of bronchial asthma in children at home and abroad,analyzes the advantages and disadvantages of first-line treatment drugs,and introduces new drug treatment methods at home and abroad,especially the application of monoclonal antibodies in new biological preparations,which provides a basis for clinical treatment of bronchial asthma in children.
作者
杨祎
姜明燕
YANG Yi;JIANG Ming-yan(China Medical University,Shenyang,Liaoning Province,110001 China;Department of Pharmacy,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,110001 China)
出处
《系统医学》
2019年第2期193-195,共3页
Systems Medicine
关键词
支气管哮喘
治疗药物
单克隆抗体
儿童
Bronchial asthma
Therapeutic drugs
Monoclonal antibodies
Children